Diagnostic Algorithms for ACS and High-Sensitivity Troponin

Slides:

Advertisements

Similar presentations

Early assessment of myocardial injury by joint measurement of TnT-hs and Copeptin (1) J. Teixeira, (2) P. Wotquenne, (2) V. D’Orio, (3) D. Gruson, (1)

Advertisements

Tobias Reichlin, W. Hochholzer, C. Stelzig, K. Laule, M. Potocki, K

for the TRAPID-AMI Investigators

Biochemical Markers of Myocardial Infarction

Sex-Specific Chest Pain Characteristics in AMI Jay Mansfield, Pgy-3 July 22, 2014 LSU Journal Club Gimenez, M, et. Al. Jama Int Med. 2014;174(2):

Biochemical Markers for Diagnosis of Myocardial Infarction Cardiovascular Block Medical Biochemistry Course Dr. Reem M. Sallam, MD, PhD.

Absolute and Relative Kinetic Changes of High-Sensitivity Cardiac Troponin T in Acute Coronary Syndrome and in Patients with Increased Troponin in the.

SPACE The Saudi Project for Assessment of Coronary Events A registry database of patients with ACS. A registry database of patients with ACS. Provides.

Ischaemic Heart Disease CASE A. CASE A: Mr HA, aged 60 years, was brought in to A&E complaining of chest pain, nausea and a suspected AMI.

Journal Club Optimizing Early Rule-Out Strategies for Acute Myocardial Infarction: Utility of 1-Hour Copeptin P. Hillinger, R. Twerenbold, C. Jaeger, K.

Implementation of a Sensitive Troponin I Assay and Risk of Recurrent Myocardial Infarction and Death in Patients With Suspected Acute Coronary Syndrome.

Biochemical Markers for Diagnosis of Myocardial Infarction

Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Implications of Introducing High-Sensitivity Cardiac.

Date of download: 7/5/2016 Copyright © 2016 American Medical Association. All rights reserved. From: One-Hour Rule-out and Rule-in of Acute Myocardial.

حسن بیات - دانش ‌ آموخته ‌ ی علوم آزمایشگاهی اردیبهشت 1395.

Incidence of Undetectable, Measurable, and Increased Cardiac Troponin I Concentrations Above the 99th Percentile Using a High-Sensitivity Versus a Contemporary.

Tobias Reichlin, M. D. , Willibald Hochholzer, M. D

Survival probability (%)

Cost Effective Use of Troponin to Rule Out Acute Coronary Syndrome

Improving Care Processes for Patients with Possible Acute Coronary Syndrome (ICARE-ACS)

One-hour rule-in and rule-out of acute myocardial infarction using high-sensitivity cardiac troponin I Cedric Jaeger, MD, Karin Wildi, MD, Raphael Twerenbold,

Timely Diagnosis of Gastroenteritis: Implications for Patients and Public Health.

Case of nonobstructive coronary artery disease of left anterior descending artery (LAD) and regional LV dysfunction detected on cardiac CT with subsequent.

Clinical Trials in IBD.

Please note this program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Part III Lessons Learned: A Master Class in High-Sensitivity Troponin A Global Perspective.

Cardiac Troponin.

Biomarker-Driven Management of Sepsis and Antibiotics Evidence and Perspectives.

Appropriate Stroke Prevention Strategies in Atrial Fibrillation

Hospitalizations in the United States Caused by ACS.

Introduction to Checkpoint Inhibitors

Cardiac Biomarkers.

Clues to a Diagnosis: A Focus on Light-Chain Amyloidosis

Ask the Onychomycosis Expert, Part 2

Identifying Patients Suitable for Discharge After a Single-Presentation High-Sensitivity Troponin Result: A Comparison of Five Established Risk Scores.

Before and After: Patient Cases in Onychomycosis

Part II: It Takes a Team— Incorporating High-Sensitivity Troponin Into Clinical Care.

Cardiac Biomarkers: Key Takeaways for Use in Heart Failure and Acute Coronary Syndrome.

Heart Failure Prevention: Mission Impossible?

A Frontline Clinician's Guide to Managing Opioid-Induced Constipation

Part I: A Sensible Approach to Sensitive Troponin

Nat. Rev. Cardiol. doi: /nrcardio

Selected Causes of Cardiac Injury PEACE Trial High-Sensitivity Biomarker Substudy.

Improving Outcomes in OSA

Learning Objectives Current Practices in Ruling Out AMI.

Advancing Acute Coronary Syndrome Assessment:

Risk Stratification in CAD and PAD

Updated Guideline Recommendations for the Definitive Diagnosis of Unexplained Syncope.

EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.

When Is Biologic Therapy Appropriate for HS?

When Is Intrathecal Drug Delivery Appropriate?

Case 1 Presentation Case 1 (cont) Assessment and Recommendations.

Managing HF in Primary Care

Undetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction Nadia Bandstein, MD; Rickard Ljung,

Undetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction Nadia Bandstein, MD; Rickard Ljung,

Chapter 18 Evaluator.

Incorporating Prostacyclins Into Practice

Program Goals Background: Anticoagulation in Patients With VTE.

High-Sensitivity Troponin in Clinical Practice

Renal Function and Myeloma Therapeutics

When Is Intrathecal Drug Delivery Appropriate?

Incorporating New PAH Treatments Into Clinical Practice

Algorithm for the investigation of patients with elevated cardiac troponin concentrations in the context of an alternative acute illness. Algorithm for.

Diagnostic Criteria Migraine Without Aura

What's New in PAH?.

My PAH Patient.

Performance of the Manchester Acute Coronary Syndromes decision rule with high-sensitivity cardiac troponin T (hs-cTnT) as the reference standard for the.

The use of 12 lead electrocardiography and cardiac troponins in the diagnostic evaluation of suspected acute coronary syndrome. *It is unusual to find.

Presentation transcript:

Diagnostic Algorithms for ACS and High-Sensitivity Troponin

Learning Objectives

Assessment of Patients With Suspected AMI

Evolution of hs-cTnT

Cardiac Troponin Evolution of Temporal Serial Sampling

hs-cTn ESC 0/3-Hour Algorithm

hs-cTnT ESC 0/1-Hour Rule-In/Rule-Out Algorithm

0/1-Hour Diagnostic Protocol Clinical Evidence

Timing of Presentation Can Influence Diagnostic Performance of hs-cTn Single Cutoff Algorithm

Diagnostic Criteria for AMI

Diagnostic Performance of hs-cTn in Patients With/Without Renal Dysfunction

Strategies for Implementation of hs-cTn

Protocol for Patient Evaluation

Advantages of hs-cTn

APACE Discharge Diagnosis

APACE Use of Coronary Angiographies

APACE Outpatient ED Stay

SWEDEHEART Registry

hs-cTnT US Label

Diagnostic Performance of Modified 0/1-Hour Algorithm Using hs-cTnT Cutoffs Approved by the FDA

Summary

Abbreviations

Abbreviations (cont)